Korean Circulation Journal

The Korean Society of Cardiology (대한심장학회)
권호 표지
DOI QR코드

DOI QR Code

Drug-Coated Balloon Treatment for De Novo Coronary Lesions: Current Status and Future Perspectives

  • Ae-Young Her (Division of Cardiology, Department of Internal Medicine, Kangwon National University College of Medicine, Kangwon National University School of Medicine) ;
  • Eun-Seok Shin (Department of Cardiology, Ulsan University Hospital, University of Ulsan College of Medicine)
  • Received : 2024.05.11
  • Accepted : 2024.05.22
  • Published : 2024.09.01
Download PDF
⟨ Previous Next ⟩

Abstract

The outstanding development in contemporary medicine, highlighted by percutaneous coronary intervention (PCI), was achieved through the adoption of drug-eluting stents (DESs). Although DES is the established therapy for patients undergoing PCI for de novo coronary artery disease (CAD), their drawbacks include restenosis, stent thrombosis, and the requirement for dual antiplatelet therapy (DAPT) with an uncertain duration regarding its optimality. Drug-coated balloon (DCB) treatment leaves nothing behind on the vessel wall, providing the benefit of avoiding stent thrombosis and not necessitating obligatory extended DAPT. After optimizing coronary blood flow, DCB treatment delivers an anti-proliferative drug directly coated on a balloon. Although more evidence is needed for the application of DCB treatment in de novo coronary lesions, recent studies suggest the safety and effectiveness of DCB treatment for diverse conditions including small and large vessel diseases, complex lesions like bifurcation lesions or diffuse or multivessel diseases, chronic total occlusion lesions, acute myocardial infarctions, patients at high risk of bleeding, and beyond. Consequently, we will review the current therapeutic choices for managing de novo CAD using DCB and assess the evidence supporting their concurrent application. Additionally, it aims to discuss future important perspectives.

Keywords

References

  1. Pilgrim T, Piccolo R, Heg D, et al. Ultrathin-strut, biodegradable-polymer, sirolimus-eluting stents versus thin-strut, durable-polymer, everolimus-eluting stents for percutaneous coronary revascularisation: 5-year outcomes of the BIOSCIENCE randomised trial. Lancet 2018;392:737-46.
  2. Kufner S, Joner M, Thannheimer A, et al. Ten-year clinical outcomes from a trial of three limus-eluting stents with different polymer coatings in patients with coronary artery disease. Circulation 2019;139:325-33.
  3. Madhavan MV, Kirtane AJ, Redfors B, et al. Stent-related adverse events >1 year after percutaneous coronary intervention. J Am Coll Cardiol 2020;75:590-604.
  4. Kong MG, Han JK, Kang JH, et al. Clinical outcomes of long stenting in the drug-eluting stent era: patient-level pooled analysis from the GRAND-DES registry. EuroIntervention 2021;16:1318-25.
  5. Scheller B, Speck U, Abramjuk C, Bernhardt U, Bohm M, Nickenig G. Paclitaxel balloon coating, a novel method for prevention and therapy of restenosis. Circulation 2004;110:810-4.
  6. Her AY, Shin ES, Bang LH, et al. Drug-coated balloon treatment in coronary artery disease: recommendations from an Asia-Pacific Consensus Group. Cardiol J 2021;28:136-49.
  7. Neumann FJ, Sousa-Uva M, Ahlsson A, et al. 2018 ESC/EACTS guidelines on myocardial revascularization. Eur Heart J 2019;40:87-165.
  8. Jeger RV, Farah A, Ohlow MA, et al. Long-term efficacy and safety of drug-coated balloons versus drug-eluting stents for small coronary artery disease (BASKET-SMALL 2): 3-year follow-up of a randomised, non-inferiority trial. Lancet 2020;396:1504-10.
  9. Rissanen TT, Uskela S, Eranen J, et al. Drug-coated balloon for treatment of de-novo coronary artery lesions in patients with high bleeding risk (DEBUT): a single-blind, randomised, non-inferiority trial. Lancet 2019;394:230-9.
  10. Lee SY, Cho YK, Kim SW, et al. Clinical results of drug-coated balloon treatment in a large-scale multicenter Korean registry study. Korean Circ J 2022;52:444-54.
  11. Ellis SG, Roubin GS, King SB 3rd, et al. Angiographic and clinical predictors of acute closure after native vessel coronary angioplasty. Circulation 1988;77:372-9.
  12. Cappelletti A, Margonato A, Rosano G, et al. Short- and long-term evolution of unstented nonocclusive coronary dissection after coronary angioplasty. J Am Coll Cardiol 1999;34:1484-8.
  13. Leimgruber PP, Roubin GS, Anderson HV, et al. Influence of intimal dissection on restenosis after successful coronary angioplasty. Circulation 1985;72:530-5.
  14. Jeger RV, Eccleshall S, Wan Ahmad WA, et al. Drug-coated balloons for coronary artery disease: third report of the International DCB Consensus Group. JACC Cardiovasc Interv 2020;13:1391-402.
  15. Shin ES, Ann SH, Balbir Singh G, Lim KH, Kleber FX, Koo BK. Fractional flow reserve-guided paclitaxel-coated balloon treatment for de novo coronary lesions. Catheter Cardiovasc Interv 2016;88:193-200.
  16. Chung JH, Lee KE, Her AY, et al. Comparison of fractional flow reserve and angiographic characteristics after balloon angioplasty in de novo coronary lesions. Int J Cardiovasc Imaging 2019;35:1945-54.
  17. Chung JH, Shin ES, Her AY, et al. Instantaneous wave-free ratio-guided paclitaxel-coated balloon treatment for de novo coronary lesions. Int J Cardiovasc Imaging 2020;36:179-85.
  18. Shin ES, Ann SH, Jang MH, et al. Impact of scoring balloon angioplasty on lesion preparation for DCB treatment of coronary lesions. J Clin Med 2023;12:6254.
  19. Ueno K, Morita N, Kojima Y, et al. Safety and long-term efficacy of drug-coated balloon angioplasty following rotational atherectomy for severely calcified coronary lesions compared with new generation drug-eluting stents. J Interv Cardiol 2019;2019:9094178.
  20. Lv S, Ma X, Zhou Y, et al. Intracoronary imaging versus coronary angiography to guide drug-coated balloon intervention in coronary artery disease: a propensity-matched pilot study analysis. Angiology 2021;72:971-8.
  21. Tanaka A, Latib A, Jabbour RJ, et al. Impact of angiographic result after predilatation on outcome after drug-coated balloon treatment of in-stent coronary restenosis. Am J Cardiol 2016;118:1460-5.
  22. Her AY, Yuan SL, Jun EJ, et al. Drug-coated balloon treatment for nonsmall de-novo coronary artery disease: angiographic and clinical outcomes. Coron Artery Dis 2021;32:534-40.
  23. Hui L, Shin ES, Jun EJ, et al. Impact of dissection after drug-coated balloon treatment of de novo coronary lesions: angiographic and clinical outcomes. Yonsei Med J 2020;61:1004-12.
  24. Shin ES, Jun EJ, Kim B. Vascular remodeling after drug-coated balloon treatment: insight from optical coherence tomography. Korean Circ J 2023;53:191-3.
  25. Ann SH, Balbir Singh G, Lim KH, Koo BK, Shin ES. Anatomical and physiological changes after paclitaxel-coated balloon for atherosclerotic de novo coronary lesions: serial IVUS-VH and FFR study. PLoS One 2016;11:e0147057.
  26. Ann SH, Her AY, Singh GB, Okamura T, Koo BK, Shin ES. Serial morphological and functional assessment of the paclitaxel-coated balloon for de novo lesions. Rev Esp Cardiol (Engl Ed) 2016;69:1026-32.
  27. Lee HS, Kang J, Park KW, et al. Procedural optimization of drug-coated balloons in the treatment of coronary artery disease. Catheter Cardiovasc Interv 2021;98:E43-52.
  28. Claessen BE, Smits PC, Kereiakes DJ, et al. Impact of lesion length and vessel size on clinical outcomes after percutaneous coronary intervention with everolimus- versus paclitaxel-eluting stents pooled analysis from the SPIRIT (Clinical Evaluation of the XIENCE V Everolimus Eluting Coronary Stent System) and COMPARE (Second-generation everolimus-eluting and paclitaxel-eluting stents in real-life practice) randomized trials. JACC Cardiovasc Interv 2011;4:1209-15.
  29. van der Heijden LC, Kok MM, Danse PW, et al. Small-vessel treatment with contemporary newer-generation drug-eluting coronary stents in all-comers: insights from 2-year DUTCH PEERS (TWENTE II) randomized trial. Am Heart J 2016;176:28-35.
  30. Cortese B, Di Palma G, Guimaraes MG, et al. Drug-coated balloon versus drug-eluting stent for small coronary vessel disease: PICCOLETO II randomized clinical trial. JACC Cardiovasc Interv 2020;13:2840-9.
  31. Kiyohara Y, Aikawa T, Kayanuma K, et al. Comparison of clinical outcomes among various percutaneous coronary intervention strategies for small coronary artery disease. Am J Cardiol 2024;211:334-42.
  32. Venetsanos D, Lawesson SS, Panayi G, et al. Long-term efficacy of drug coated balloons compared with new generation drug-eluting stents for the treatment of de novo coronary artery lesions. Catheter Cardiovasc Interv 2018;92:E317-26.
  33. Toelg R, Merkely B, Erglis A, et al. Coronary artery treatment with paclitaxel-coated balloon using a BTHC excipient: clinical results of the international real-world DELUX registry. EuroIntervention 2014;10:591-9.
  34. Uskela S, Karkkainen JM, Eranen J, et al. Percutaneous coronary intervention with drug-coated balloon-only strategy in stable coronary artery disease and in acute coronary syndromes: an all-comers registry study. Catheter Cardiovasc Interv 2019;93:893-900.
  35. Her AY, Shin ES, Lee JM, et al. Paclitaxel-coated balloon treatment for functionally nonsignificant residual coronary lesions after balloon angioplasty. Int J Cardiovasc Imaging 2018;34:1339-47.
  36. Her AY, Shin ES, Chung JH, et al. Plaque modification and stabilization after paclitaxel-coated balloon treatment for de novo coronary lesions. Heart Vessels 2019;34:1113-21.
  37. Poerner TC, Duderstadt C, Goebel B, Kretzschmar D, Figulla HR, Otto S. Fractional flow reserve-guided coronary angioplasty using paclitaxel-coated balloons without stent implantation: feasibility, safety and 6-month results by angiography and optical coherence tomography. Clin Res Cardiol 2017;106:18-27.
  38. Hu FW, Chang S, Li Q, et al. Long-term clinical outcomes after percutaneous coronary intervention with drug-coated balloon-only strategy in de novo lesions of large coronary arteries. Front Cardiovasc Med 2022;9:882303.
  39. Gitto M, Sticchi A, Chiarito M, et al. Drug-coated balloon angioplasty for de novo lesions on the left anterior descending artery. Circ Cardiovasc Interv 2023;16:e013232.
  40. Lin Y, Sun X, Liu H, Pang X, Dong S. Drug-coated balloon versus drug-eluting stent for treating de novo coronary lesions in large vessels: a meta-analysis of clinical trials. Herz 2021;46:269-76.
  41. Park TK, Park YH, Song YB, et al. Long-term clinical outcomes of true and non-true bifurcation lesions according to medina classification- results from the COBIS (COronary BIfurcation Stent) II registry. Circ J 2015;79:1954-62.
  42. Pan M, Lassen JF, Burzotta F, et al. The 17th expert consensus document of the European Bifurcation Club - techniques to preserve access to the side branch during stepwise provisional stenting. EuroIntervention 2023;19:26-36.
  43. Kleber FX, Rittger H, Ludwig J, et al. Drug eluting balloons as stand alone procedure for coronary bifurcational lesions: results of the randomized multicenter PEPCAD-BIF trial. Clin Res Cardiol 2016;105:613-21.
  44. Corballis NH, Paddock S, Gunawardena T, Merinopoulos I, Vassiliou VS, Eccleshall SC. Drug coated balloons for coronary artery bifurcation lesions: a systematic review and focused meta-analysis. PLoS One 2021;16:e0251986.
  45. Her AY, Ann SH, Singh GB, et al. Serial morphological changes of side-branch ostium after paclitaxelcoated balloon treatment of de novo coronary lesions of main vessels. Yonsei Med J 2016;57:606-13.
  46. Pan L, Lu W, Han Z, et al. Drug-coated balloon in the treatment of coronary left main true bifurcation lesion: a patient-level propensity-matched analysis. Front Cardiovasc Med 2022;9:1028007.
  47. Okutsu M, Mitomo S, Ouchi T, et al. Impact of directional coronary atherectomy followed by drug-coated balloon strategy to avoid the complex stenting for bifurcation lesions. Heart Vessels 2022;37:919-30.
  48. Kitani S, Igarashi Y, Tsuchikane E, et al. Efficacy of drug-coated balloon angioplasty after directional coronary atherectomy for coronary bifurcation lesions (DCA/DCB registry). Catheter Cardiovasc Interv 2021;97:E614-23.
  49. Costopoulos C, Latib A, Naganuma T, et al. The role of drug-eluting balloons alone or in combination with drug-eluting stents in the treatment of de novo diffuse coronary disease. JACC Cardiovasc Interv 2013;6:1153-9.
  50. Yang X, Lu W, Pan L, et al. Long-term outcomes of drug-coated balloons in patients with diffuse coronary lesions. Front Cardiovasc Med 2022;9:935263.
  51. Shin ES, Jun EJ, Kim S, et al. Clinical impact of drug-coated balloon-based percutaneous coronary intervention in patients with multivessel coronary artery disease. JACC Cardiovasc Interv 2023;16:292-9.
  52. Lee CW, Park DW, Lee BK, et al. Predictors of restenosis after placement of drug-eluting stents in one or more coronary arteries. Am J Cardiol 2006;97:506-11.
  53. Mieres J, Fernandez-Pereira C, Risau G, et al. One-year outcome of patients with diabetes mellitus after percutaneous coronary intervention with three different revascularization strategies: results from the Diabetic Argentina Registry (DEAR). Cardiovasc Revasc Med 2012;13:265-71.
  54. Wohrle J, Scheller B, Seeger J, et al. Impact of diabetes on outcome with drug-coated balloons versus drug-eluting stents: the BASKET-SMALL 2 trial. JACC Cardiovasc Interv 2021;14:1789-98.
  55. Her AY, Shin ES, Kim S, et al. Drug-coated balloon-based versus drug-eluting stent-only revascularization in patients with diabetes and multivessel coronary artery disease. Cardiovasc Diabetol 2023;22:120.
  56. Sharp AS, Latib A, Ielasi A, et al. Long-term follow-up on a large cohort of "full-metal jacket" percutaneous coronary intervention procedures. Circ Cardiovasc Interv 2009;2:416-22.
  57. Lee PH, Lee SW, Yun SC, et al. Full metal jacket with drug-eluting stents for coronary chronic total occlusion. JACC Cardiovasc Interv 2017;10:1405-12.
  58. Wohrle J, Werner GS. Paclitaxel-coated balloon with bare-metal stenting in patients with chronic total occlusions in native coronary arteries. Catheter Cardiovasc Interv 2013;81:793-9.
  59. Jun EJ, Shin ES, Teoh EV, et al. Clinical outcomes of drug-coated balloon treatment after successful revascularization of de novo chronic total occlusions. Front Cardiovasc Med 2022;9:821380.
  60. Sung JG, Lo ST, Lam H. Contemporary interventional approach to calcified coronary artery disease. Korean Circ J 2023;53:55-68.
  61. Stone SG, Serrao GW, Mehran R, et al. Incidence, predictors, and implications of reinfarction after primary percutaneous coronary intervention in ST-segment-elevation myocardial infarction: the Harmonizing Outcomes with Revascularization and Stents in Acute Myocardial Infarction Trial. Circ Cardiovasc Interv 2014;7:543-51.
  62. Vos NS, Fagel ND, Amoroso G, et al. Paclitaxel-coated balloon angioplasty versus drug-eluting stent in acute myocardial infarction: the REVELATION randomized trial. JACC Cardiovasc Interv 2019;12:1691-9.
  63. Scheller B, Ohlow MA, Ewen S, et al. Bare metal or drug-eluting stent versus drug-coated balloon in non-ST-elevation myocardial infarction: the randomised PEPCAD NSTEMI trial. EuroIntervention 2020;15:1527-33.
  64. Kondo Y, Ishikawa T, Shimura M, et al. Cardiovascular outcomes after paclitaxel-coated balloon angioplasty versus drug-eluting stent placement for acute coronary syndrome: a systematic review and meta-analysis. J Clin Med 2024;13:1481.
  65. Palmerini T, Della Riva D, Benedetto U, et al. Three, six, or twelve months of dual antiplatelet therapy after DES implantation in patients with or without acute coronary syndromes: an individual patient data pairwise and network meta-analysis of six randomized trials and 11473 patients. Eur Heart J 2017;38:1034-43.
  66. Shin ES, Lee JM, Her AY, et al. Prospective randomized trial of paclitaxel-coated balloon versus bare-metal stent in high bleeding risk patients with de novo coronary artery lesions. Coron Artery Dis 2019;30:425-31.
  67. Rowinsky EK, Donehower RC. Paclitaxel (taxol). N Engl J Med 1995;332:1004-14.
  68. Clever YP, Cremers B, Krauss B, et al. Paclitaxel and sirolimus differentially affect growth and motility of endothelial progenitor cells and coronary artery smooth muscle cells. EuroIntervention 2011;7 Suppl K:K32-42.
  69. Verheye S, Vrolix M, Kumsars I, et al. The SABRE Trial (Sirolimus Angioplasty Balloon for Coronary In-Stent Restenosis): angiographic results and 1-year clinical outcomes. JACC Cardiovasc Interv 2017;10:2029-37.
  70. Scheller B, Mangner N, Abdul Kader MA, et al. Combined analysis of two parallel randomized trials of sirolimus-coated and paclitaxel-coated balloons in coronary in-stent restenosis lesions. Circ Cardiovasc Interv 2022;15:e012305.
  71. Cortese B, Testa L, Heang TM, et al. Sirolimus-coated balloon in an all-comer population of coronary artery disease patients: the EASTBOURNE prospective registry. JACC Cardiovasc Interv 2023;16:1794-803.
  72. Stettler C, Wandel S, Allemann S, et al. Outcomes associated with drug-eluting and bare-metal stents: a collaborative network meta-analysis. Lancet 2007;370:937-48.
  73. Ahmad WA, Nuruddin AA, Abdul Kader MA, et al. Treatment of coronary de novo lesions by a sirolimusor paclitaxel-coated balloon. JACC Cardiovasc Interv 2022;15:770-9.
  74. Ninomiya K, Serruys PW, Colombo A, et al. A prospective randomized trial comparing sirolimus-coated balloon with paclitaxel-coated balloon in de novo small vessels. JACC Cardiovasc Interv 2023;16:2884-96.
  75. Gao XF, Ge Z, Kan J, et al. Rationale and design for comparison of non-compliant balloon with drug-coating balloon angioplasty for side branch after provisional stenting for patients with true coronary bifurcation lesions: a prospective, multicentre and randomised DCB-BIF trial. BMJ Open 2022;12:e052788.
  76. Greco A, Sciahbasi A, Abizaid A, et al. Sirolimus-coated balloon versus everolimus-eluting stent in de novo coronary artery disease: rationale and design of the TRANSFORM II randomized clinical trial. Catheter Cardiovasc Interv 2022;100:544-52.